Ord Minnett Sticks to Its Buy Rating for Immutep Ltd (PRRUF)
TipRanks (Wed, 17-Dec 7:35 PM ET)
Market Chameleon (Wed, 17-Dec 6:48 AM ET)
Immutep Highlights Progress in TACTI-004 Phase III Cancer Trial
TipRanks (Wed, 17-Dec 6:28 AM ET)
Globe Newswire (Tue, 16-Dec 8:00 AM ET)
Market Chameleon (Mon, 8-Dec 5:30 AM ET)
Globe Newswire (Mon, 8-Dec 8:00 AM ET)
Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
Globe Newswire (Tue, 2-Dec 8:00 AM ET)
Globe Newswire (Thu, 13-Nov 8:00 AM ET)
Immutep Receives A$4.6 million R&D Tax Incentive from French Government
Globe Newswire (Mon, 3-Nov 8:00 AM ET)
Immutep Quarterly Activities Report Q1 FY26
Globe Newswire (Wed, 29-Oct 8:00 AM ET)
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Immutep Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol IMMP.
As of December 19, 2025, IMMP stock price climbed to $2.63 with 348,156 million shares trading.
IMMP has a beta of 1.26, meaning it tends to be more sensitive to market movements. IMMP has a correlation of 0.13 to the broad based SPY ETF.
IMMP has a market cap of $387.11 million. This is considered a Small Cap stock.
In the last 3 years, IMMP traded as high as $3.90 and as low as $1.32.
The top ETF exchange traded funds that IMMP belongs to (by Net Assets): IBB.
IMMP has outperformed the market in the last year with a price return of +21.2% while the SPY ETF gained +17.3%. IMMP has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +55.6% and +47.8%, respectively, while the SPY returned +3.3% and -0.6%, respectively.
IMMP support price is $2.48 and resistance is $2.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMMP shares will trade within this expected range on the day.
